Amneal settles derivative suit over KSP acquisition; royalty cut, governance changes

Amneal Pharmaceuticals, Inc.

Amneal agreed to reduce Kashiv royalties by 1.15% on three products until $11.5M NPV cap is reached.
Attorneys' fees capped at $2M, subject to court approval; settlement hearing set for July 25, 2023.
Governance changes include independent Delaware counsel for related-party transactions and stockholder vote on deals >$100M.
Deborah M. Autor added to Amneal board and Conflicts Committee as independent director.
Settlement resolves claims that 2021 KSP acquisition was unfair; no admission of wrongdoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.